The U.S. Supreme Court recently ruled that businesses cannot control the rights to human genes in their natural state. Patients' rights groups are calling the decision a victory. The court, 61 , left room to protect the patent ownership rights on some 62 important biotechnology applications.
The court's decision was in a case 63 (involve) the biotechnology company Myriad Genetics. The company 64 (identify) human genes that increase a woman's risk for breast cancer and ovarian cancer. The company applied for and was given exclusive rights 65 the use of those genes.
Attorney Sandra Park works with the American Civil Liberties Union. She says the U.S. Patent and Trademark Office has been allowing patents on some DNA for66 years.
“What was 66 (problem) about these patents was that Myriad was able to use those patents to stop other laboratories from providing genetic testing, even 67 those other laboratories were using different methods.”
Miss Park says that means that genetic testing for 68 risk of breast and ovarian cancer cost more because of the lack of competition. And she says the gene patent prevented patients from getting 69 second medical opinion based on some other test.
But the Supreme Court has now rejected this type of patent; all nine justices agreed that 70 genes are products of nature, they can not be owned by one business.